30 Day Trial

ORTHOWORLD » Other Articles of Interest

New Appointments at AAOS, Active Implants

The American Academy of Orthopaedic Surgeons/AAOS selected Thomas E. Arend, Jr., CAE as Chief Executive Officer, effective April 1, 2017. The appointment follows the retirement of Karen L. Hackett, FACHE, CAE after 14 years as AAOS' CEO.

Arend is leaving a position as Executive Vice President, Chief Operating Officer and General Counsel at the American College of Cardiology where, since 2004, he managed the entity's financial health, operations and strategic direction. Further, he was responsible for all aspects of the College’s legal, risk management and compliance activities.

Like his predecessor, Mr. Arend will oversee a staff of 250 and manage an annual budget of $60 million.

From BONEZONE: AAOS President, Gerald R. Williams Jr., M.D., answers the question,
"Where will the greatest change come in orthopaedics in the next five years?"


Active Implants, developer of the NUsurface® Meniscus Implant, named Ted Davis as President and CEO, succeeding Henry Klyce who has moved to Chairman of Active Implants' board.

Mr. Davis' previous appointments include CEO of MicroPort Orthopedics and President of Wright Medical Technology’s global OrthoRecon division following ten years in life sciences venture capital, employed at MB Venture Partners and Vector Fund Management.

In 2Q16, Active Implants announced the first meniscus replacement in the SUN (Safety Using NUsurface) clinical trial, investigating the treatment for patients with persistent knee pain following medial meniscus surgery.